Every letter we have printed

The point I would press is documentation. Whatever schedule is followed, writing down the dose, the date and what happened turns an anecdote into a small dataset. Most of the confusion I hear about comes from people who cannot reconstruct what they did.

Weight trajectories in the published trials flatten well before the study ends, and the curve shape is one of the most useful things a reader can be shown. Expectations set on the early gradient are set on a section of a curve that does not continue.

The most useful thing your department has published on this was the comparison of curve shapes across studies with the horizons marked. Seeing where each line stops does more for a reader’s calibration than any amount of argument about mechanism.

Escalating in response to a plateau is discussed as though the relationship between exposure and effect were linear beyond the studied range. It is not, in any published dose-response data I have seen, and the curve flattens there too.

The tolerability curve and the efficacy curve have different shapes, and the interesting region is where they diverge. Almost all discussion of ceilings addresses one curve at a time.

An approved schedule is a regulatory artefact reflecting what was submitted and what was studied, and it is read as a statement about what is optimal. Those are different things and the gap between them is not evidence of anything.

Retailers who buy from wholesalers display the wholesaler’s badge. The mark then describes material two steps removed from the vial being sold, and every party in the chain has behaved reasonably. Aggregation is where most of the misleading happens and no rule addresses it.

A defence of the practice, since you have printed several attacks. Before badges existed there was no public evidence of any testing at all. The current arrangement is a poor version of a good idea and it is still an improvement on what preceded it.

I keep a bound notebook for submissions: date, molecule, lot, weight sent, courier, tracking, laboratory, report number. It is unglamorous, it takes two minutes an entry, and it has made me the only party in several conversations with an actual record.

Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.

A practical note from a service bench. Sodium and potassium adducts are the commonest reason a first spectrum looks wrong, and they come from the glassware and the water rather than from the sample. Before anybody concludes a peptide is not what it says it is, they should check whether the offset is twenty-two.

Charge-state distribution is diagnostic and almost always discarded. A peptide that normally presents as a triply and quadruply charged pair, appearing this time as a broad ladder, is telling you something about its conformation or its buffer. The information is in the file and never in the summary.

Endotoxin is invisible to everything you describe and to everything most buyers commission. It is not a purity question, it is not an identity question, and it is not answered by any instrument in this article. Saying so plainly is worth a paragraph in its own right.

Aggregates are the other invisible class, and for a different reason: they do not survive the ionisation. A sample that is substantially aggregated can give an entirely clean monomer spectrum, because the instrument is reporting on what made it into the gas phase.

Appetite returning is the mechanism and it is worth saying so directly, because the alternative explanations readers reach for are usually about willpower. Removing an appetite intervention returns appetite; that is what the intervention was doing.

The regain trajectory is presented as a mean curve and the variation around it is very wide. Some participants hold most of the change and some return close to baseline, and the average describes neither of them well.

A supply-side observation. Where somebody has settled on one source for a long commitment, a change in that source’s manufacturing is a change in their arrangement, and it happens without announcement. Your dossier work is the only place I have seen this treated as a continuity question.

The curves everybody reproduces are drawn from the last available observation for participants who left early, which is a specific analytical choice with a known direction of bias. Alternative analyses are usually in the appendix and rarely differ dramatically, but readers should know one was made.

Analytical quality matters more over a long horizon than a short one, which is a point this publication is well placed to make. A material used once is a single exposure; a material used for years is a cumulative one, and the standard a buyer applies should rise accordingly.

Exposure varies several-fold between individuals at the same nominal dose, which means a population ceiling and a personal one are different numbers. The pharmacokinetic variability is published and rarely quoted.

Dose-ranging studies are the most informative and least cited part of this literature. They were run before the approved schedules were settled and they contain the evidence everybody is now arguing about without reading.

I want to object to the framing of dose reduction as measurement. In practice it is experienced as failure, and telling people it is a thermostat does not change how the appointment feels. The language problem is real and you have solved it rhetorically rather than actually.

The gap between the printed schedule and the practised one is real and your piece is right to describe it without approving of it. The label schedule was the one studied; every departure from it is an extrapolation, and the people making those departures are rarely the people who would be asked to defend them.

The practical advice I would want printed is to write down the date of the last dose. It sounds trivial and it is the single piece of information that makes the re-titration question answerable, and it is the one people most often cannot supply.

What I would like to see published is simply the proportion of suppliers who offer the test as a paid extra. It is a fact somebody could establish in a fortnight of correspondence, and it would tell readers where the market actually stands.

Water is the usual source. A synthesis and purification chain that uses water of unspecified quality has an endotoxin exposure at every step, and none of it is visible in a purity determination.

The statistics section is the part of this I will be sending to people. I had assumed a passed sterility test meant something about the batch. It had not occurred to me that a batch with one contaminated vial in a hundred passes four times out of five.

A verified badge on a seller’s own page supports exactly one claim: that a document exists. It cannot support a claim about the lot in front of the buyer unless the badge resolves to a report identifying that lot, and almost none of them do.

My objection is narrower than most of your correspondents’. I do not mind an undated badge on a page about a company. I mind an undated badge beside a price, because the proximity makes a claim about that product which nothing in the mark supports.

The distinction that matters is not blind against named but who chose the sample. A blind submission of a vial the seller selected is not blind in any sense that protects the reader, and the word is doing all the work in that sentence.

An observation from the receiving end. When we are sent numbered samples with no context we ask more questions of the data, because we cannot lean on an expectation. Blinding improves the analysis as well as the credibility, and that argument is never made.

You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.

A note on species differences that catches people out. Receptor pharmacology established in rodent tissue does not transfer cleanly, and several of the older mechanistic claims in circulation rest on preparations that were never human. Your citation practice is better than most on this point.

The class B receptor architecture is worth a diagram for readers who last saw this at university. A large extracellular domain that captures the peptide, then a second interaction with the transmembrane core: it explains immediately why these are peptides and not tablets, and why the small-molecule agonists that do exist had to solve a different problem.

Compensatory adaptation over weeks is the systematic limit on any acute mechanistic account, and it is not measurable in the assays that generate the mechanistic claims.

Nothing in receptor pharmacology predicts who will respond, and the between-individual spread in the trials is wide. Until there is a marker that identifies a responder in advance, the pharmacology explains the average and is silent about the person.

A short letter to make one point. Nobody in this area distinguishes between stopping the substance and stopping the monitoring, and the second is at least as consequential. People who continue without measuring anything have made a different decision from people who stopped.

Supply interruption is a reason people stop that has nothing to do with anybody’s decision, and it produces the same physiological sequence as a planned stop with none of the preparation. The supply reporting elsewhere in the issue is directly relevant here.

The costs compound quietly. A monthly figure that seemed acceptable at the start becomes a substantial annual commitment, and almost nobody in the accounts I read did that arithmetic before beginning.

Participants who complete a run-in and are then randomised are a selected group by construction, so the withdrawal arm is populated by people who tolerated and responded. Generalising from them to everybody who stops overstates what is known.